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Cardiac resynchronization therapy with
defibrillator
Inappropriate ICD therapya b s t r a c t
Introduction: Various risk factors for the first inappropriate implantable cardioverter-defibrillator (ICD)
therapy event have been reported, including a history of atrial fibrillation/atrial flutter (AF/AFL), younger
age, and multiple zones. Nonetheless, which factors are concordant with real-world data has not been
clarified, and risk factors for the second inappropriate ICD therapy event have not been well examined.
This study aimed to clarify the risk factors for the first and second inappropriate ICD therapy events.
Methods: We conducted a post-hoc secondary analysis of data from a multicenter, prospective observa-
tional study (the Nippon Storm Study) designed to clarify the risk factors for electrical storm.
Results: The analysis included data from 1549 patients who received ICD or cardiac resynchronization
therapy with defibrillator (CRT-D). Over a median follow-up of 28 months, 293 inappropriate ICD therapy
events occurred in 153 (10.0%) patients. On multivariate Cox regression analysis, the risk factors for the
first inappropriate ICD therapy event were younger age (hazard ratio [HR], 0.986; p = 0.028), AF/AFL (HR,
2.324; p = 0.002), ICD without CRT implantation (HR, 2.377; p = 0.004), and multiple zones (HR, 1.852;
p = 0.010). ‘‘No-intervention” after the first inappropriate ICD therapy event was the sole risk factor
for the second inappropriate ICD therapy event.
Conclusions: Risk factors for the first inappropriate ICD therapy event were similar to those previously
reported. Immediate intervention after the first inappropriate ICD therapy event could reduce the risk
of the second inappropriate event.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Implantable cardioverter-defibrillator (ICD), including cardiac
resynchronization therapy with defibrillator (CRT-D), has become
an established therapeutic option for the primary and secondary
prevention of sudden arrhythmic death via treatment of ventricu-
lar tachyarrhythmias [1–3]. However, it is known that somepatients receive inappropriate ICD therapy for sinus tachycardia,
atrial tachycardia, atrial fibrillation (AF), atrial flutter (AFL),
T-wave oversensing, or nonphysiological noise. Furthermore, inap-
propriate ICD-delivered shocks can cause anxiety and death [4–7].
Since the publication of early ICD trials [1–3], there have been sig-
nificant advances in ICD technology as well as substantial changes
in device programming to lower the risk of inappropriate ICD ther-
apy [8–10]. Although the risk factors for the first inappropriate ICD
therapy event have been reported [11–14], patients in daily prac-
tice may substantially differ from those included in pivotal trials.
This raises the question as to whether risk factors for the first inap-
propriate ICD therapy event are the same as those previously
reported. Additionally, the management after the first inappropri-
ate ICD therapy event seems to be important to prevent the second
inappropriate ICD therapy event; however, this has not been well
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tive observational study investigating electrical storm events. In
1570 patients who received ICD or CRT-D, the incidence rate of
electrical storm was 6.6% (84 of 1570 patients) over a median
follow-up of 28 months. The present study aimed to clarify the risk
factors for the first and second inappropriate ICD therapy events
among patients enrolled in the Nippon Storm Study.2. Methods
2.1. Study population
The present study is a post-hoc secondary analysis of patients
enrolled in the Nippon Storm Study. The design and primary
results of the Nippon Storm Study have been published [15,16].
Briefly, the Nippon Storm Study was organized by the Japanese
Heart Rhythm Society and the Japanese Society of Electrocardiol-
ogy. Web-based registration of patients was conducted in 48 Japa-
nese ICD centers (see Appendix), with the Japanese Heart Rhythm
Society collecting data from the physicians who input patients’
data. All 1570 patients provided their written informed consent,
and the study protocol was approved by the Institutional Review
Board and/or Medical Ethics Committee of each center.2.2. ICD programing
The ICD was programmed at the physician’s discretion. Some
discrimination algorithms, such as PR Logic and Wavelet (Medtro-
nic, Minneapolis, MN), Rhythm ID (Boston Scientific, Marlborough,
MA) and Morphology Discrimination plus AV Rate Branch (St. Jude
Medical, St. Paul, MN), were used. In most patients, the ventricular
fibrillation (VF) zone was >188–220 bpm, with at least one train of
antitachycardia pacing (ATP) before the ICD-delivered shock, and
the ventricular tachycardia (VT) zone was >140–180 bpm, with
at least three trains of ATP before the ICD-delivered shock,
although modifications were permitted based on each patient’s
background. The single zone included only a VF zone, and multiple
zones included both VF and VT zones.2.3. Follow-up
To provide a precise follow-up, we constructed a new tracking
system, the ‘‘Chaser,” which was intended to minimize the loss
of follow-up data. Intervention data (both appropriate and inap-
propriate ICD therapy) were sent to the office of the Japanese Heart
Rhythm Society, using a dedicated website, at a maximum interval
of 6 months. The ICD therapeutic interventions were classified into
ATP, low-energy shocks, and high-energy shocks.
The following baseline patient characteristics were assessed:
age, sex, underlying heart disease, indication of ICD (primary or
secondary), and complications related to the implantation proce-
dure. An inappropriate ICD therapy was defined as any inappropri-
ate ATP or ICD shock for sinus tachycardia, AF/AFL, regular
supraventricular tachycardia, or non-arrhythmic events (such as
detected noise, myopotentials, electromagnetic interference, and
T-wave oversensing). The primary outcome of our study was the
incidence rate and the risk factors for the first and second inappro-
priate ICD therapy events. The time period between the first and
second inappropriate ICD therapy events was also included in the
analysis. Inappropriate ICD therapy episodes occurring incessantly
or during short periods of fewer than 6 h were regarded as the first
inappropriate ICD therapy event, not as the second or third inap-
propriate ICD therapy event.2
2.4. Statistical analysis
Baseline characteristics were evaluated between patients with
and without inappropriate ICD therapy. Continuous data were
reported as a mean ± standard deviation (SD), or median and
interquartile range (IQR), as appropriate for the data distribution,
with between-group differences evaluated using Student’s t-test
or the Wilcoxon’s rank-sum test. Categorical data were summa-
rized as frequencies and percentages, with between-group differ-
ences compared using Pearson’s chi-squared test. The 95%
confidence intervals (CI) for the proportion of lead failures detected
by arrhythmic events were also calculated. Between-group differ-
ences in the time-to-detection (reported as a mean ± SD or median
and IQR, as appropriate for the distribution of data) were evaluated
using Student’s t-test or Wilcoxon’s rank-sum test. Cumulative
probability of inappropriate ICD therapy rate was reported using
the Kaplan-Meier method, with between-group differences in the
cumulative event rate evaluated using the log-rank test. Multivari-
ate Cox proportional hazards regression analysis was conducted to
identify the independent risk factors for the first and second
inappropriate ICD therapy events. All tests were two-sided, and a
p-value <0.05 was considered statistically significant. All statistical
analyses were performed using R software version 3.4.2 (R Project
for Statistical Computing).3. Results
3.1. Patient characteristics
Among 1570 patients enrolled in the Nippon Storm Study from
48 ICD centers in Japan, data on inappropriate ICD therapies were
not available for 21 patients, while the data of the remaining 1549
patients were included in our analysis. The baseline characteristics
of these 1549 patients are summarized in Table 1. At the time of
implantation, the average age of patients was 62.5 years, with
1209 (78.1%) patients being men. An ICD was implanted in 1048
(67.7%) patients, with CRT-D used in the other 501 (32.3%)
patients. The median left ventricular ejection fraction (LVEF) before
implantation was 38%, with ICD indicated for major causes of
structural heart disease, namely ischemic heart disease in 486
(31.4%) patients and dilated cardiomyopathy (DCM) in 347
(22.4%). Patient characteristics based on device type (ICD or CRT-
D) are also presented in Table 1.
3.2. Inappropriate ICD therapy
Over a median follow-up of 28 months, 293 inappropriate ICD
therapy events occurred in 153 out of 1549 (10.0%) patients. The
causes of inappropriate ICD therapy were sinus tachycardia in 35
events, atrial tachyarrhythmia in 175 events, T-wave oversensing
in 7 events, electromagnetic interference in 1 event, myopotential
in 1 event, and not available in 74 events.
3.3. Risk factors for the first inappropriate ICD therapy
The Kaplan-Meier curve indicated that the cumulative rate of
inappropriate ICD therapy events was 6.9% at 12 months
(Fig. 1A). Differences between baseline characteristics of patients
with and without the first inappropriate ICD therapy event are
described in Table 1. No between-group differences in the distribu-
tion of sex, age, symptoms of heart failure, LVEF, baseline heart rate
or medication were identified. However, patients with AF/AFL were
significantly more likely to receive inappropriate ICD therapy than
those without AF/AFL (inappropriate ICD therapy; 15.8% vs. 9.4%,
p = 0.003). The incidence rate of inappropriate ICD therapy was
Table 1
Patient characteristics based on the first inappropriate ICD therapy.
Total Inappropriate ICD therapy () Inappropriate ICD therapy (+) p ICD CRT-D p
N 1549 1396 153 1048 501
Male, n (%) 1209 (78.1) 1095 (78.4) 114 (74.5) 0.312 828 (79.0) 379 (75.6) 0.195
Age, years 62.5 (14.2) 62.7 13.9) 60.2 (16.4) 0.039 60.7 (15.2) 66.1 (11.0) <0.001
Heart disease, n (%) 0.099 <0.001
Ischemic heart disease 486 (31.4) 449 (32.2) 37 (24.2) 340 (32.4) 146 (29.1)
Dilated cardiomyopathy 347 (22.4) 312 (22.3) 35 (22.9) 111 (10.6) 236 (47.1)
Hypertrophic cardiomyopathy 195 (12.6) 171 (12.2) 24 (15.7) 167 (15.9) 28 (5.6)
ARVC 30 (1.9) 25 (1.8) 5 (3.3) 25 (2.4) 5 (1.0)
Cardiac sarcoidosis 61 (3.9) 58 (4.2) 3 (2.0) 58 (4.2) 3 (2.0)
Brugada syndrome 135 (8.7) 125 (9.0) 10 (6.5) 135 (12.9) 0 (0.0)
Ideopathic ventricular fibrillation 80 (5.2) 70 (5.0) 10 (6.5) 80 (7.6) 0 (0.0)
Others 215 (13.9) 186 (13.3) 29 (19.0) 132 (12.6) 87 (17.4)
Primary prevention, n (%) 731 (47.2) 666 (47.7) 65 (42.5) 0.253 369 (35.2) 362 (72.3) <0.001
Scondary prevention, n (%) 818 (52.8) 730 (52.3) 88 (57.5) 679 (64.8) 139 (27.7)
Type of CIED, n (%) <0.001 <0.001
ICD 1048 (67.7) 921 (66.0) 127 (83.0) – –
CRT-D 501 (32.3) 475 (34.0) 26 (17.0) – –
Single chamber, n (%) 329 (21.2) 290 (20.8) 39 (25.5) 0.211 271 (25.9) 61 (12.2) <0.001
NYHA class, n (%) 0.102 <0.001
I 637 (41.1) 567 (40.6) 70 (45.8) 617 (58.9) 20 (4.0)
II 492 (31.8) 438 (31.4) 54 (35.3) 330 (31.5) 162 (32.3)
III 368 (23.8) 344 (24.6) 24 (15.7) 95 (9.1) 273 (54.5)
IV 52 (3.4) 47 (3.4) 5 (3.3) 6 (0.6) 46 (9.2)
Ejection fraction, % 42.6 (18.7) 42.3 (18.6) 45.0 (19.3) 0.090 49.5 (18.1) 27.0 (9.4) <0.001
Log BNP 2.2 (0.7) 2.2 (0.7) 2.2 (0.7) 0.773 2.0 (0.7) 2.6 (0.5) <0.001
Serum creatinine, mg/dl 1.3 (1.5) 1.3 (1.4) 1.3 (2.0) 0.911 1.2 (1.2) 1.6 (2.0) <0.001
Atrial rhythm, n (%) 0.003 <0.001
Sinus rhythm 1256 (81.1) 1137 (81.4) 119 (77.8) 915 (87.3) 341 (68.1)
Atrial fibrillation/Atrial flutter 190 (12.3) 160 (11.5) 30 (19.6) 100 (9.5) 90 (18.0)
Others 103 (6.6) 99 (7.1) 4 (2.6) 33 (3.1) 70 (14.0)
Heart rate 66.3 (14.2) 66.1 (14.2) 67.5 (14.5) 0.253 64.9 (13.1) 69.0 (15.9) <0.001
QRS duration, ms 126.9 (35.2) 128.1 (35.7) 116.4 (28.9) <0.001 112.8 (27.0) 156.2 (32.4) <0.001
QT interval, ms 440.1 (57.2) 441.1 (57.6) 431.2 (52.9) 0.042 431.1 (57.0) 462.1 (57.0) <0.001
Death, % 144 (9.3) 134 (9.6) 10 (6.5) 0.275 76 (7.3) 68 (13.6) <0.001
Inappropriate ICD therapy, % – – – – 127 (12.1) 26 (5.2) <0.001
Comorbidity, n (%)
Hypertension 609 (39.3) 546 (39.1) 63 (41.2) 0.682 417 (39.8) 192 (38.3) 0.617
Diabetes mellitus 395 (25.5) 375 (26.9) 20 (13.1) <0.001 230 (21.9) 165 (32.9) <0.001
Dyslipidemia 423 (27.3) 387 (27.7) 36 (23.5) 0.313 296 (28.2) 127 (25.3) 0.247
Cerebral infarction 105 (6.8) 96 (6.9) 9 (5.9) 0.768 69 (6.6) 36 (7.2) 0.666
Cerebral hemorrage 17 (1.1) 16 (1.1) 1 (0.7) 0.884 12 (1.1) 5 (1.0) 1.000
Peripheral atrery disease 32 (2.1) 30 (2.1) 2 (1.3) 0.692 20 (1.9) 12 (2.4) 0.568
Medication, n (%)
Beta blocker 875 (56.5) 793 (56.8) 82 (53.6) 0.500 534 (51.0) 341 (68.1) <0.001
ACE-I 440 (28.4) 397 (28.4) 43 (28.1) 1.000 247 (23.6) 193 (38.5) <0.001
ARB 421 (27.2) 377 (27.0) 44 (28.8) 0.714 256 (24.4) 165 (32.9) <0.001
Class III antiarrhythmic drugs 520 (33.6) 480 (34.4) 40 (26.1) 0.050 345 (32.9) 175 (34.9) 0.455
Program
Single zone, n (%) 428 (28.5) 397 (29.4) 31 (20.4) 0.025 328 (31.3) 23.4 (20.0) <0.001
Multiple zones, n (%) 1074 (71.5) 953 (70.6) 121 (79.6) 720 (68.7) 401 (80.0)
minimum cut-off rate, bpm 166.2 (24.4) 166.7 (24.5) 161.5 (22.9) 0.013 168.3 (25.3) 161.5 (21.6) <0.001
Values are mean (standard deviation), median [interquartile range] or number (%) of patients.
ARVC denotes arrhythmogenic right ventricular cardiomyopathy, NYHA New York Heart Association, BNP brain natriuretic peptide.
ICD denotes implantable cardioverter defibrillator, CRT-D cardiac resynchronization therapy with defibrillator.
ACE-I denotes angiotensin converting enzyme inhibitor, ARB angiotensin receptor, bpm beat per minute.
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(12.1% vs. 5.1%, p < 0.001). The baseline QRS width and QT interval
were significantly shorter in patients who received inappropriate
ICD therapy than those who did not (QRS width: 120 vs. 110 ms,
respectively, p < 0.001; QT interval: 438 vs. 420 ms, respectively,
p = 0.027). The incidence of inappropriate ICD therapy was greater
in patients treated using multiple zones than in those treated using
a single zone (11.2% vs. 7.2%, p = 0.025). The minimum cut-off rate
was significantly lower in patients who received inappropriate ICD
therapy than those who did not (161.5 vs. 168.3 bpm, p < 0.001).
On multivariate Cox regression analysis, younger age (hazard
ratio [HR], 0.986; 95% CI, 0.973–0.998; p = 0.028), AF/AFL (HR,
2.324; 95% CI, 1.372–3.939; p = 0.002), ICD without CRT implanta-
tion (HR, 2.377; 95% CI, 1.332–4.244; p = 0.004), and multiple
zones (HR, 1.852; 95% CI, 1.163–2.951, p = 0.010) were identified3
as risk factors for the first inappropriate ICD therapy event
(Table 2).
The Kaplan-Meier curves indicated a significantly higher risk for
the first inappropriate ICD therapy event in patients with AF/AFL
than in those without AF/AFL at 12 months (14.4% vs. 5.9%, log-
rank p = 0.001; Fig. 1B). The risk of the first inappropriate ICD ther-
apy event was significantly higher in patients treated with an ICD
than in those treated with CRT-D at 12 months (8.7% vs. 3.1%, log-
rank p < 0.001; Fig. 1C).3.4. Risk factors for the second inappropriate ICD therapy event
After the first inappropriate ICD therapy event, the following
interventions were performed, including a change in the ICD pro-
gramming (n = 89), initiation of or change in medication (n = 23)
Fig. 1. Cumulative probability of (A) an inappropriate ICD therapy event; (B) an inappropriate ICD therapy among patients with and without atrial tachyarrhythmia prior to
enrollment; and (C) an inappropriate ICD therapy among patients treated with ICD and CRT-D.
Table 2
Multivariate Cox regression analysis for the first inappropriate ICD therapy.
Inappropriate ICD therapy
HR (95% CI) p
Age 0.986 (0.973, 0.998) 0.028
Male 0.779 (0.512, 1.187) 0.246
Atrial fibrillation/Atrial flutter 2.324 (1.372, 3.939) 0.002
QRS duration 0.994 (0.987, 1.000) 0.060
ICD 2.377 (1.332, 4.244) 0.004
Without atrial lead 0.932 (0.571, 1.520) 0.779
NYHA class, III/IV 0.996 (0.589, 1.685) 0.990
Ejection fraction, % 0.995 (0.983, 1.006) 0.369
Log BNP 1.146 (0.818, 1.606) 0.428
Electrical storm 0.750 (0.346, 1.625) 0.466
Secondary prevention 0.957 (0.662, 1.385) 0.817
Multiple zones 1.852 (1.163, 2.951) 0.010
BNP denotes brain natriuretic peptide and was log 10 transformed.
ICD denotes implantable cardioverter defibrillator.
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tions. Among the 89 ICD programming changes, 42 raised the
detection zone of VT or VF, while the remaining 47 changes were
precisely unknown. Precise medication change and catheter abla-
tion data were also unavailable. The rate of the second inappropri-
ate ICD therapy event after treatment for the first event was 37.6%
at 12 months (Fig. 2A). The Kaplan-Meier curve indicated that the4
rate of the second inappropriate ICD therapy event was lower
among patients who received treatment after the first event than
among those who did not (1.0% vs. 6.0% at one week, 4.2% vs.
22.3% at one month, 27.3% vs. 57.4% at one year, respectively, all
log-rank p < 0.001; Fig. 2B). On multivariate Cox regression analy-
sis, ‘‘no-intervention” after the first inappropriate ICD therapy
event was retained as the sole risk factor for the second inappropri-
ate ICD therapy event (HR, 3.521; 95% CI, 1.773–6.993; p = 0.001;
Table 3).4. Discussion
4.1. New findings
Our post-hoc secondary analysis identified younger age, ICD
without CRT implantation, history of AF/AFL, and multiple zones
as risk factors for the first inappropriate ICD therapy event. Treat-
ment after the first inappropriate ICD therapy event, including ini-
tiation of (or change in) medication and change in ICD
programming and ablation, lowered the risk of the second inappro-
priate ICD therapy event. The risk factor for the second inappropri-
ate ICD therapy event was ‘‘no-intervention” after the first
inappropriate ICD therapy event.
Fig. 2. Cumulative probability of the second event of inappropriate ICD therapy (A) after the first event of inappropriate ICD therapy among all patients and (B) among
patients with or without treatment after the first event. An inappropriate ICD therapy includes both inappropriate anti-tachycardia pacing and shock.
Table 3
Multivariate Cox regression analysis for a second inappropriate ICD therapy.
Inappropriate ICD
therapy







Atrial fibrillation/Atrial flutter 1.547 (0.574,
4.168)
0.389






Without atrial lead 0.856 (0.337,
2.173)
0.744
NYHA class, III/IV 1.099 (0.419,
2.882)
0.848
Ejection fraction, % 0.997 (0.977,
1.018)
0.797
Log BNP 0.873 (0.512,
1.489)
0.619
Electrical storm 0.642 (0.149,
2.776)
0.554
Secondary prevention 1.739 (0.840,
3.600)
0.136
Multiple zones 2.170 (0.793,
5.937)
0.132





BNP denotes brain natriuretic peptide and was log 10 transformed.
ICD denotes implantable cardioverter defibrillator.
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Several therapeutic interventions after the first inappropriate
ICD therapy event have been used, including a change in ICD pro-
gramming, initiation of (or change in) medication, and catheter
ablation [17] Korte et al. [18] tried atrio-ventricular nodal catheter
ablation, cavo-tricuspid isthmus ablation and pulmonary vein iso-
lation in patients suffered from repetitive inappropriate ICD thera-
pies. The inappropriate ICD therapy rate was significantly reduced
after catheter ablation. Miyazaki et al. [19] reported the recurrent
rate of inappropriate ICD therapy in 18 patients who received inap-
propriate ICD therapy due to atrial tachyarrhythmia and undertook5
catheter ablation. During the median follow-up of 19.0 (9.5–37.3)
months after the last procedure, no patients experienced any inap-
propriate shocks. A change in ICD programming or medication
have been tried first after the first inappropriate ICD therapy. In
our study, main interventions were also a change in ICD program-
ming or initiation of (or change in) after inappropriate ICD therapy.
Catheter ablation may be aggressively tried. Our study identified
that treatment after the first inappropriate ICD therapy event low-
ered the risk for the second event. This is an important finding as
more frequent events of inappropriate ICD therapy is associated
with poor clinical outcomes and higher mortality rate [4,5]. As
such, prevention of the second inappropriate ICD therapy event
is as important as prevention of the first inappropriate ICD therapy
event. Recently, remote monitoring has been shown to be useful
for the prevention of inappropriate ICD therapy [20,21]. Although
there is no information of remote monitoring in the present study,
remote monitoring may also play a major role in detecting an inap-
propriate ICD therapy event, allowing for an appropriate treatment
that could prevent a subsequent inappropriate ICD therapy event
as early as possible [20].4.3. ICD versus CRT-D
In a small retrospective cohort analysis of prospectively col-
lected data, Chen et al. [11] reported a lower rate of inappropriate
ICD shock for CRT-D than ICD treatment. Similarly, Kutyifa et al.
[12] reported a lower risk of inappropriate ICD therapy and shock
among patients implanted with a CRT-D than among those
implanted with an ICD (inappropriate therapy, 6% vs. 12%, respec-
tively; shock, 2% vs. 5%, respectively). These findings were consis-
tent with those of our study. The better outcomes for CRT-D may
be due to an improvement in the functional capacity of CRT-D,
compared to ICD, to induce reverse remodeling of the left atrium,
which leads to a significant decrease in atrial tachy-arrhythmia
[22–24]. Along with the result that a lower rate of inappropriate
ICD shock for CRT-D than ICD, baseline QRS width and QT interval
were significantly shorter in patients with inappropriate ICD ther-
apy than those without (Table 1).
Conduction disturbance may be another reason for the lower
inappropriate ICD therapy rate in patients with CRT-D than in
those with ICD. During AF, a rapid ventricular response may not
occur because of intrinsic conduction disturbance; consequently,
inappropriate ICD therapy could be avoided.
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Notably, atrial tachycardia and AF/AFL are the most frequent
reasons for inappropriate ICD therapy. In the MADIT-II trial [5],
inappropriate ICD shocks occurred in 83 out of 719 patients
(11.5%). AF/AFL was the most common mechanism of inappropri-
ate shock. A sub-analysis of the MADIT-RIT data [13] indicated that
patients with a history of AF were at a higher risk for inappropriate
ICD therapy (HR, 2.10; 95% CI, 1.38–3.20; p < 0.001) and inappro-
priate ICD shock (HR, 2.56; 95% CI, 1.38–4.74; p = 0.003) than
patients without a prior history of AF. Recently, the stability crite-
ria and morphological template have been available to avoid inap-
propriate ICD therapy due to AF/AFL. However, rapid ventricular
response events could be particularly stable and likely conduct
aberrantly, followed by inappropriate ICD therapy. In our study,
AF/AFL was also identified as a risk factor for inappropriate ICD
therapy. ICD programming should be optimized in all patients irre-
spective of a history of atrial tachyarrhythmia, not only in those
currently known to have a higher risk of inappropriate ICD therapy.4.5. Age
A sub analysis of the MADIT-RIT data [14] identified an inverse
relationship between age and inappropriate ICD therapy. The
cumulative Kaplan-Meier incidence curves revealed an inverse
relationship between increasing quartiles of age (Q1: 55, Q2:
56–64, Q3: 65–71, and Q4: 72 years) and inappropriate ICD ther-
apy events. In agreement with our study, an inappropriate ICD
therapy event was more likely to occur in younger than older
patients. As previously reported [14], despite the higher frequency
of atrial tachyarrhythmia among older patients, the attenuated
ventricular response might offer some protection to older patients
against inappropriate ICD therapy.4.6. Single zone versus multiple zones
Single zone or multiple zones options are available in recent ICD
models, allowing the application of different stimulation criteria to
various locations of arrhythmias. Additionally, as some manufac-
turers also include supraventricular tachycardia discrimination
algorithms, programming for more than one tachycardia zone
allows for greater specificity in discriminating VT from supraven-
tricular tachycardia. Although the effectiveness of single-zone
and multiple-zone programming has not been specifically evalu-
ated in a head-to-head comparison, in the MADIT-RIT study [9],
the single-zone arm (high rate) was comparable to the triple-
zone (delayed) arm with regard to inappropriate shock. In our pre-
sent study, the rate of inappropriate ICD therapy was significantly
higher for multiple zones than for a single zone. However, consis-
tent with the findings of previous studies, there was no significant
difference in the inappropriate ICD shock between these two
groups (data not shown). Multiple zones had a lower cut-off rate
than the single zone (155.4 vs. 193.3 bpm, p < 0.001), and patients
treated using multiple zones were more likely to suffer from inap-
propriate ICD therapy. Actually, the minimum cut-off rate was sig-
nificantly lower in patients who received inappropriate ICD
therapy than in those who did not in this study. The cut-off rate
for the lowest zone was relatively low as compared to that in the
previous study. More than 50% of patients in this study were
implanted ICR or CRT-D for secondary prevention. Class III antiar-
rhythmic drugs were used in more than 30% of patients, in whom
the VT rate was likely to decrease. Therefore, these were the main
reasons for the low cut-off heart rate.6
4.7. Limitations
The limitations of our study need to be acknowledged in the
interpretation of findings. First, our analysis is a post-hoc sec-
ondary analysis, which carries the bias inherent to this type of
analysis. Second, there is no information in the Nippon Storm
Study to discriminate AF from atrial tachycardia and AFL; there-
fore, precise analysis based on the type of atrial tachyarrhythmia
was not possible. Third, clinical characteristics between patients
in the ICD and CRT-D groups, as well as between the groups of
patients with and without AF/AFL, were different, which may have
influenced the predictors of inappropriate ICD therapy that we
identified. Fourth, precise algorithms for discriminating supraven-
tricular tachycardia, including morphological template, stability
criteria, and sudden-onset data, were not available, making it
impossible to analyze the effectiveness of each algorithm.5. Conclusions
This is the first study to have focused on identifying predictive
factors for the first and second inappropriate ICD therapy events.
Risk factors for the first inappropriate ICD therapy event were sim-
ilar to those previously reported. Immediate intervention after the
first inappropriate ICD therapy event could reduce the likelihood of
the second inappropriate ICD therapy event. Overall, our study pro-
vides information that can help to guide physicians in making deci-
sions about the type of ICD treatment and the follow-up required.Funding
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Appendix A. The 48 participating Japanese implantable cardiac
shock device centers in the present study
Hokko Memorial Hospital
Second Department of Internal Medicine, Sapporo Medical
University Hospital
Department of Cardiovascular Medicine, Hokkaido University
Hospital
Department of Cardiovascular Medicine, Hirosaki University
Graduate School
Department of Cardiovascular Medicine, Tohoku University
Hospital
Cardiovascular Division, Faculty of Medicine, University of
Tsukuba
Department of Internal Medicine, Jichi Medical University
Division of Cardiology, Gunma Prefectural Cardiovascular
Center
N. Nishii, T. Noda, T. Nitta et al. IJC Heart & Vasculature 34 (2021) 100779Cardiovascular Medicine, Saitama Medical University Interna-
tional Medical Center
Department of Cardiology, Juntendo University Urayasu
Hospital
Department of Cardiovascular Medicine, Chiba University
Hospital
Division of Cardiology, Sakakibara Heart Institute
First Department of Medicine, Nippon Medical School Hospital
Department of Cardiology, Keio University School of Medicine
Department of Cardiovascular Medicine, Tokyo Metropolitan
Hiroo Hospital
Division of Cardiology, Department of Medicine, Showa
University
Department of Cardiology, Jikei University School of Medicine
Department of Cardio-angiology, Kitasato University
Department of Heart Rhythm Management, Yokohama Rosai
Hospital
Yokohama City University School of Medicine, Department of
Medical Science and Cardiorenal Medicine
Showa University Fujigaoka Hospital
Department of Cardiology, Yokohama Minami Kyousai Hospital
Department of Cardiovascular Biology and Medicine, Niigata
University Graduate School of Medical and Dental Sciences
Division of Cardiology, Tachikawa General Hospital
Department of Cardiovascular Medicine, Shinshu University
School of Medicine, Graduate School of Medicine
Department of Cardiology, Nagoya University
Cardiovascular Medicine, Toyohashi Heart Center
Japanese Red Cross Nagoya Daini Hospital
Department of Cardiology, Fujita Health University School of
Medicine
Cardiovascular Medicine, Kyoto University Hospital
Department of Cardiovascular Medicine, Kyoto Prefectural
University School of Medicine
Cardiovascular Center, Sakurabashi Watanabe Hospital
Department of Cardiovascular Medicine, National Cerebral and
Cardiovascular Center
Division of Cardiology, Department of Medicine, Faculty of
Medicine, Kinki University
Department of Cardiovascular Medicine, Osaka City University
Hospital
Department of Cardiology, Osaka General Medical Center
Department of Cardiology, Hyogo Brain And Heart Center
Department of Cardiology, Kobe University Hospital
Department of Cardiovascular Medicine, Okayama University
Department of Cardiovascular Surgery, Hiroshima University
Graduate School of Medicine
Division of Cardiology, Department of Internal Medicine II,
Yamaguchi University Hospital
Department of Cardiology, Ehime University Graduate School of
Medicine
Department of Cardiovascular Medicine, Kokura Memorial
Hospital
Department of Cardiology, Fukuoka University School of
Medicine
Department of Heart Rhythm Management, University of Occu-
pational and Environmental Health
Department of Cardiology, Saiseikai Kumamoto Hospital
Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University
Department of Cardiology, Okinawa Prefectural Chubu Hospital7
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